Gilead is committing $109m to a drug discovery partnership with Goldfinch Bio, which has developed the Kidney Genome Atlas of genetics and clinical data regarding the kidney. In the meantime, they’ve been building some strength on the AI side, looking to create a computational group that can plumb the data they’ve been gathering to help spotlight targets and drugs. The kidney genome atlas will be used by researchers in Australia and around the world to understand how genes influence disease risk for people who have had their kidneys removed. Goldfinch CEO Tony Johnson said the start-up will consider launching an IPO once it is closer to proof of concept data for new drugs.
Gilead is committing $109m to a drug discovery partnership with Goldfinch Bio, which has developed the Kidney Genome Atlas of genetics and clinical data regarding the kidney. The kidney genome atlas will be used by researchers in Australia and around the world to understand how genes influence disease risk for people who have had their kidneys removed. Goldfinch CEO Tony Johnson said the start-up will consider launching an IPO once it is closer to proof of concept data for new drugs.